Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.179 USD | -5.28% | -6.47% | -23.73% |
May. 09 | Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 569K | Sales 2025 * | 675K | Capitalization | 24.21M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -48M | EV / Sales 2024 * | 42.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 35.9 x |
P/E ratio 2024 * |
-0.68
x | P/E ratio 2025 * |
-0.97
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.77% |
Latest transcript on Oncternal Therapeutics, Inc.
1 day | -5.28% | ||
1 week | -6.47% | ||
Current month | -1.58% | ||
1 month | -8.51% | ||
3 months | -17.22% | ||
6 months | +41.02% | ||
Current year | -23.73% |
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 96-12-31 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 17-03-31 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 96-12-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 19-06-06 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 21-01-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 8.179 | -5.28% | 2,568 |
24-05-09 | 8.635 | +0.94% | 1,695 |
24-05-08 | 8.555 | +0.41% | 737 |
24-05-07 | 8.52 | -5.33% | 11,112 |
24-05-06 | 9 | +2.92% | 3,481 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.73% | 24.21M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ONCT Stock